Motilal Oswal - Zensar Technologies (ZENT) MOSL: ZENSAR TECHNOLOGIES (Buy)-Traction in growth and margins despite tight supply

Report

Motilal Oswal

EUR 120.00 For Business Accounts Only

MOSL: ZENSAR TECHNOLOGIES (Buy)-Traction in growth and margins despite tight supply

Zensar Technologies: Traction in growth and margins despite tight supply

(ZENT IN, Mkt Cap USD0.8b, CMP INR256, TP INR300, 17% Upside, Buy)

We attended the RPG Group analyst meet, where ZENT management shared its views on the key verticals and the strategy going ahead. Key highlights:

Targeting Digital to be two thirds of revenues in next three years

Digital contributes 45% of revenues and is expected to exceed 60% in 3-4 years.
Hi-Tech remains the key vertical, which is expected to drive this digital growth. Customers from Independent Software Vendors (ISVs) and Internet/Social/Mobile (ISM) sub-segments are spending heavily on digital which needs to be tapped. Acquisition of Indigo Slate and Foolproof has helped add more clients in this segment.
Digital has only slightly higher onsite mix than non-digital. From 2,200 digital employees, 1,200 are in the US and the rest are based in the UK and South Africa.

13/06/2019 1 EN

Underlying

Zensar Technologies

Zensar Technologies offers a comprehensive range of I.T. services including software development, packaged software implementation and system maintenance services to its worlwide customers operating in different industries. Co. also offers remote services in the voice and non-voice categories.

See profile

INE520A01019 India

Provider

Motilal Oswal

Motilal Oswal Financial Services Ltd. is a reputed name in Financial Services and Online Trading with group companies providing services such as Private Wealth Management, Retail Broking and Distribution, Institutional Broking, Asset Management, Investment Banking, Private Equity, Commodity Broking, Currency Broking, Principal Strategies & Home Finance.

Motilal Oswal Securities is a group company of Motilal Oswal Financial Service Limited which started as a stock trading company and has blossomed into well diversified firm offering a range of financial products and services. Motilal Oswal has built a reputation as the source for best stock trading company and this has taken a wealth of experience, knowledge and expertise, constantly working in tandem, over the years.

See profile

Other Reports on these Companies

SmartInsider

Zensar Technologies Ltd: 1 director

A director at Zensar Technologies Ltd sold 17,930 shares at 685.926INR and the significance rating of the trade was 73/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The name...

Free Trial

October 30, 2024 October 30, 2024 1 EN

Motilal Oswal

MOSL: ZENSAR TECHNOLOGIES (Buy)- Revenue growth takes a pause

ZENSAR TECHNOLOGIES: Revenue growth takes a pause (ZENT IN, Mkt Cap USD0.6b, CMP INR199, TP INR280, 41% Upside, Buy) Soft topline, steady margins: 2QFY20 revenue increased 12.8% YoY (v/s est. of 14.8%) to USD152m. EBIT increased 6.2% YoY to INR1,115m (margin of 10.4%) v/s our expectation of 5.2% decline YoY. Despite higher operational income, PAT declined 16% YoY to INR799m (v/s est. of INR843m) led by higher interest expense at INR139m (v/s est. of INR39m) and lower other income at INR9m (v/s est. of INR74m). Deal completion drags revenue growth: ZENT reported 15.8% QoQ drop in the CI...

EUR 120.00

October 23, 2019 October 23, 2019 14 EN

Motilal Oswal

MOSL: ZENSAR TECHNOLOGIES (Buy)-Traction in CIS-deal pipeline remains healthy

ZENSAR TECHNOLOGIES: Traction in CIS; deal pipeline remains healthy (ZENT IN, Mkt Cap USD0.7b, CMP INR217, TP INR286, 32% Upside, Buy) Operating performance above expectations: ZENT's 1QFY20 revenue grew 16.4% YoY (estimate: +12.2% YoY) to USD153m, while EBIT increased 6% YoY (our estimate: +2% YoY) to INR1,136m (margin of 10.7%). Despite higher operational income, PAT declined 5.8% YoY to INR787m (our estimate: INR833m) due to higher interest expense (INR166m v/s our estimate of INR45m) and lower other income (INR38m v/s our estimate of INR74m). Increase in revenue was a function of a ...

EUR 120.00

August 8, 2019 August 8, 2019 1 EN

MOSL : HOME FIRST FINANCE COMPANY: Earnings in-line with sustained improvement in asset quality

HOME FIRST FINANCE COMPANY: Earnings in-line with sustained improvement in asset quality (HOMEFIRS IN, Mkt Cap USD0.9b, CMP INR802, TP INR1025, 28% Upside, Buy) HomeFirst’s 2QFY23 PAT grew 21% YoY/6% QoQ to INR543m (in-line). Credit costs grew 37% QoQ to INR50m (MOFSLe: INR31m). Underlying this, the NII grew 58% YoY to ~INR1b (in-line). ‘Other income’ grew 13% QoQ, driven primarily by higher treasury gains and investment income. Opex was 7% higher than estimated and grew 47% YoY and 14% QoQ, led by investments in new branches and resultant higher employee expenses. Disbursements grew 36%...

EUR 120.00

October 21, 2022 October 21, 2022 12 EN

Aliasgar Shakir

Aliasgar Shakir

MOSL : SHOPPERS STOP: Ticking the right boxes

. SHOPPERS STOP: Ticking the right boxes (SHOP IN, Mkt Cap USD1b, CMP INR780, TP INR805, 3% Upside, Neutral) Aided by price hikes, SHOP reported a healthy 19% revenue growth in 2QFY23 from pre-COVID levels (8% beat) on healthy (+10%) SSSG and sustained volumes. EBITDA grew 2.3x YoY (22% over pre-COVID levels), with a 540bp margin improvement. 1) A strong recovery in revenue, backed by an improved pricing; 2) expansion within the Beauty and Private Label segment; and 3) healthy annual 12/15 store additions for SHOP/Beauty are expected to drive business growth going forward. We expect a r...

EUR 120.00

October 21, 2022 October 21, 2022 13 EN

Tushar Manudhane

Tushar Manudhane

MOSL : ERIS LIFESCIENCES: Enhanced efforts toward product launch-related activities

ERIS LIFESCIENCES: Enhanced efforts toward product launch-related activities (ERIS IN, Mkt Cap USD1.2b, CMP INR708, TP INR860, 21% Upside, Buy) Eris Lifesciences (ERIS) delivered better than expected 2QFY23 performance, led by superior traction in new launches and improved operating leverage. ERIS is notonly sustaining the momentum in its recently launched products, but it is also preparing itself for an aggressive pace of new introductions. We reiterate our earnings estimate for FY23/FY24 and continue to value ERIS at 22x 12M forward earnings to arrive at a price target of INR860. We re...

EUR 120.00

October 21, 2022 October 21, 2022 11 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

MOSL: ZENSAR TECHNOLOGIES (Buy)-Traction in growth and margins despite tight supply

Zensar Technologies Ltd: 1 director

MOSL: ZENSAR TECHNOLOGIES (Buy)- Revenue growth takes a pause

MOSL: ZENSAR TECHNOLOGIES (Buy)-Traction in CIS-deal pipeline remains healthy

MOSL : HOME FIRST FINANCE COMPANY: Earnings in-line with sustained improvement in asset quality

MOSL : SHOPPERS STOP: Ticking the right boxes

MOSL : ERIS LIFESCIENCES: Enhanced efforts toward product launch-related activities

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe